4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Prone Position in Acute Bronchiolitis (PROPOSITIS)

Prone Position in Acute Bronchiolitis (PROPOSITIS)

Study Description
Brief Summary:

Acute viral bronchiolitis is the leading cause of community-acquired acute respiratory failure in developed countries (20 000 to 30 000 hospitalizations each year in France). Between 5% and 22% of these children are hospitalized in a critical care unit to benefit from a respiratory support.

Non-invasive ventilation, in particular the nasal Continuous Positive Airway Pressure (nCPAP), reduces the work of breathing in children with bronchiolitis and is associated with decreased morbidity and hospitalization costs compared with invasive ventilation. Nowadays, this technique is considered as the gold standard in the pediatric intensive care units (PICU) in France. High Flow Nasal Cannula (HFNC) has been proposed as an alternative to the nCPAP because of its better tolerance and simplicity of implementation. However, the proportion of failure remains high (35 to 50%), providing only a partial response to the care of these children, especially prior to the PICU.

In a physiological study (NCT02602678, article published), it has been demonstrated that prone position (PP) decrease, by almost 50%, the respiratory work of breathing and improve the respiratory mechanics in infants hospitalized in intensive care units for bronchiolitis.

Investigators hypothesize that prone position, during High Flow Nasal Cannula (HFNC), would significantly reduce the use of non-invasive ventilation (nCPAP and others) or invasive ventilation, as compared to supine position during HFNC, in infants with moderate to severe viral bronchiolitis.


Condition or disease Intervention/treatment Phase
Acute Viral Bronchiolitis Procedure: Supine position (SP) Procedure: Prone position (PP) Not Applicable

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Effect of Prone Position on the Use of Non-invasive and Invasive Ventilation in Infants With Moderate to Severe Acute Bronchiolitis
Actual Study Start Date : January 13, 2021
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2022
Arms and Interventions
Arm Intervention/treatment
Supine position (SP)
Supine position (SP) combined with HFNC
Procedure: Supine position (SP)

Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.

Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.


Experimental: Prone position (PP)
Prone position (SP) combined with HFNC
Procedure: Prone position (PP)

Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.

Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.


Outcome Measures
Primary Outcome Measures :
  1. Proportion of ventilated children in each of the 2 groups [ Time Frame: 3 days ]

    Indications for the use of ventilation (invasive or non-invasive ventilation) will be standardized in both groups (based on the interregional protocol for the management of bronchiolitis):

    • Clinical aggravation defined by an increase ≥ 1 point of the m-WCAS score
    • Persistence of hypercapnic acidosis with pH ≤7.30 and pCO2≥ 8 kPa or FiO2> 60% under HFNC at 2 L/kg/min
    • More than 2 significant apneas per hour (apnea with desaturation <90% and / or bradycardia <90 / min)
    • Consciousness disorder

    Anytime over the first 3 days after inclusion



Secondary Outcome Measures :
  1. Proportion of failure [ Time Frame: 3 days ]

    Failure is defined as:

    • HFNC failure (composite failure criterion validated by an independent committee)
    • worsening of mWCAS score ≥ 1 point
    • hypercapnic acidosis (pH ≤7.30 and pCO2≥8kPa)
    • significant apnea (apnea with desaturation <90% and / or bradycardia <90/min)

    Anytime over the first 3 days after inclusion


  2. Causes of failure [ Time Frame: 3 days ]

    Failure is defined as:

    • HFNC failure (composite failure criterion validated by an independent committee)
    • worsening of mWCAS score ≥ 1 point
    • hypercapnic acidosis (pH ≤7.30 and pCO2≥8kPa)
    • significant apnea (apnea with desaturation <90% and / or bradycardia <90/min)

    Anytime over the first 3 days after inclusion


  3. Duration of ventilation [ Time Frame: maximum 3 months ]

    Duration of ventilation (high flow nasal cannula, invasive, non-invasive) in hours.

    This data will be collected at critical care unit discharge.


  4. Length of stay [ Time Frame: maximum 3 months ]
    Length of stay in days. This data will be collected at hospital discharge.

  5. Oxygenation evaluation [ Time Frame: 2 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H2.

  6. Oxygenation evaluation [ Time Frame: 12 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H12.

  7. Oxygenation evaluation [ Time Frame: 24 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H24.

  8. Tolerance evaluation [ Time Frame: maximum 3 months ]

    Proportion of skin lesions, vomiting/regurgitation and exclusive enteral nutrition.

    This data will be collected at critical care unit discharge.


  9. Variation EDIN score (Scale of pain and discomfort of the newborn) between inclusion and after 2 hours [ Time Frame: 2 hours ]

    Scale ranges to 0 from 15 and is a combination of criteria:

    • Face: Relaxed=0 to Permanent tightness or prostrate face,frozen or purple face=3
    • Body: Relaxed=0 to Permanent agitation,tightness of extremities and stiffness of limbs or very poor and limited motor skills with fixed body=3
    • Sleep:Easily, extended and calm=0 to No sleep=3
    • Relationship:Smile to the angels,smile answer,attentive to the listening=0 to Refuses contact,no relationship possible,howl or moan without any stimulation=3
    • Comfort: Do not need comfort=0 to Inconsolable,desperate sucking=3

  10. Evaluation of the feasibility of maintaining the position [ Time Frame: 48 hours ]
    Proportion of children in the prone position repositioned definitively in the supine position before performing the cumulative 24 hours of prone position, cumulative hours of prone position in the first 48 hours


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   up to 6 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Infant under 6 months
  • Hospitalized in critical care unit (continuous monitoring unit or intensive care unit)
  • With a clinical diagnosis of acute viral bronchiolitis during the epidemic period (criterion of the American Academy of Pediatrics 2014)
  • m-WCAS score ≥ 3 and / or hypercapnic acidosis with pH <7.35 and pCO2> 50mmHg (6.7 kPa)
  • Informed consent signed by at least one of the parents with oral consent of the other parent (and / or legal guardian) recorded in the medical file.

Exclusion Criteria:

  • Infant admitted with criteria for invasive or non-invasive ventilation (hypercapnic acidosis with pH <7.25 without ventilatory support, hypoxia with impossibility of maintaining SpO2> 92% whatever the FiO2, more than 3 significant apneas per hour, severe consciousness disorder)
  • Patient already positioned in the prone position before randomization
  • Significant comorbidities with a history of respiratory pathology (bronchodysplasia), Ear Nose and Throat pathology (pharyngolaryngomalacia) or neuromuscular and / or hemodynamically significant congenital heart disease.
  • Contraindication to Prone position : recent abdominal surgery (laparoschisis or omphalocele) or recent sternotomy
  • Patient who is not affiliated (or does not benefit from) to a national social security system
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Florent BAUDIN, Dr 04 72 12 97 35 ext +33 florent.baudin@chu-lyon.fr
Contact: Tiphanie GINHOUX 04 27 85 77 23 ext +33 tiphanie.ginhoux@chu-lyon.fr

Locations
Layout table for location information
France
Réanimation pédiatrique et unité de surveillance continue - Hôpital Femme Mère Enfant - Hospices Civils de Lyon Recruiting
Bron, France, 69500
Contact: Florent BAUDIN, Dr    04 72 12 97 35 ext +33    florent.baudin@chu-lyon.fr   
Contact: Tiphanie GINHOUX    04 27 85 77 23 ext +33    tiphanie.ginhoux@chu-lyon.fr   
Principal Investigator: Florent BAUDIN, Dr         
CH CHAMBERY Unité de surveillance continue pédiatrique Recruiting
Chambéry, France, 73000
Contact: Corinne PAGET    04 79 96 61 60 ext +33    Corinne.Paget@ch-metropole-savoie.fr   
CH VILLEFRANCHE Service de pédiatrie néonatologie Recruiting
Gleizé, France, 69400
Contact: Marie TOCHON TEIXEIRA    04 74 09 28 39 ext +33    MTochon@lhopitalnordouest.fr   
CHU GRENOBLE Service de réanimation pédiatrique Hôpital Couple Enfant Recruiting
La Tronche, France, 38700
Contact: Guillaume MORTAMET    04 76 76 55 03 ext +33    gmortamet@chu-grenoble.fr   
CHU MONTPELLIER Service de réanimation pédiatrique Recruiting
Montpellier, France, 34295
Contact: Christophe MILESI    04 67 33 66 09 ext +33    c-milesi@chu-montpellier.fr   
CHU Nantes Unité de surveillance continue pédiatrique Hôpital mère-enfant Recruiting
Nantes, France, 44093
Contact: Jean Eudes PILOQUET       piloquet.jeaneudes@gmail.com   
CHU LENVAL NICE Service de réanimation pédiatrique Recruiting
Nice, France, 06200
Contact: Mickael AFFANETI    04 92 03 04 08 ext +33    afanetti.m@pediatrie-chulenval-nice.fr   
Hôpital Necker Enfant Malade, Paris Service de Réanimation et surveillance continue médicochirurgicales Recruiting
Paris, France, 75015
Contact: Sylvain RENOLLEAU    01 44 49 56 67 ext +33    sylvain.renolleau@aphp.fr   
CHU SAINT-ETIENNE Service de réanimation pédiatrique Recruiting
Saint-Priest-en-Jarez, France, 42270
Contact: François BARRIERE    04 77 82 83 85 ext +33    francois.barriere@chu-st-etienne.fr   
CH ANNECY GENEVOIS Unité de surveillance continue pédiatrique Recruiting
Épagny, France, 74370
Contact: Clémence JARASSE    04 50 63 63 24 ext +33    cjarrasse@ch-annecygenevois.fr   
Sponsors and Collaborators
Hospices Civils de Lyon
Tracking Information
First Submitted Date  ICMJE June 3, 2019
First Posted Date  ICMJE June 6, 2019
Last Update Posted Date January 22, 2021
Actual Study Start Date  ICMJE January 13, 2021
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 5, 2019)
Proportion of ventilated children in each of the 2 groups [ Time Frame: 3 days ]
Indications for the use of ventilation (invasive or non-invasive ventilation) will be standardized in both groups (based on the interregional protocol for the management of bronchiolitis):
  • Clinical aggravation defined by an increase ≥ 1 point of the m-WCAS score
  • Persistence of hypercapnic acidosis with pH ≤7.30 and pCO2≥ 8 kPa or FiO2> 60% under HFNC at 2 L/kg/min
  • More than 2 significant apneas per hour (apnea with desaturation <90% and / or bradycardia <90 / min)
  • Consciousness disorder
Anytime over the first 3 days after inclusion
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 6, 2019)
  • Proportion of failure [ Time Frame: 3 days ]
    Failure is defined as:
    • HFNC failure (composite failure criterion validated by an independent committee)
    • worsening of mWCAS score ≥ 1 point
    • hypercapnic acidosis (pH ≤7.30 and pCO2≥8kPa)
    • significant apnea (apnea with desaturation <90% and / or bradycardia <90/min)
    Anytime over the first 3 days after inclusion
  • Causes of failure [ Time Frame: 3 days ]
    Failure is defined as:
    • HFNC failure (composite failure criterion validated by an independent committee)
    • worsening of mWCAS score ≥ 1 point
    • hypercapnic acidosis (pH ≤7.30 and pCO2≥8kPa)
    • significant apnea (apnea with desaturation <90% and / or bradycardia <90/min)
    Anytime over the first 3 days after inclusion
  • Duration of ventilation [ Time Frame: maximum 3 months ]
    Duration of ventilation (high flow nasal cannula, invasive, non-invasive) in hours. This data will be collected at critical care unit discharge.
  • Length of stay [ Time Frame: maximum 3 months ]
    Length of stay in days. This data will be collected at hospital discharge.
  • Oxygenation evaluation [ Time Frame: 2 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H2.
  • Oxygenation evaluation [ Time Frame: 12 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H12.
  • Oxygenation evaluation [ Time Frame: 24 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H24.
  • Tolerance evaluation [ Time Frame: maximum 3 months ]
    Proportion of skin lesions, vomiting/regurgitation and exclusive enteral nutrition. This data will be collected at critical care unit discharge.
  • Variation EDIN score (Scale of pain and discomfort of the newborn) between inclusion and after 2 hours [ Time Frame: 2 hours ]
    Scale ranges to 0 from 15 and is a combination of criteria:
    • Face: Relaxed=0 to Permanent tightness or prostrate face,frozen or purple face=3
    • Body: Relaxed=0 to Permanent agitation,tightness of extremities and stiffness of limbs or very poor and limited motor skills with fixed body=3
    • Sleep:Easily, extended and calm=0 to No sleep=3
    • Relationship:Smile to the angels,smile answer,attentive to the listening=0 to Refuses contact,no relationship possible,howl or moan without any stimulation=3
    • Comfort: Do not need comfort=0 to Inconsolable,desperate sucking=3
  • Evaluation of the feasibility of maintaining the position [ Time Frame: 48 hours ]
    Proportion of children in the prone position repositioned definitively in the supine position before performing the cumulative 24 hours of prone position, cumulative hours of prone position in the first 48 hours
Original Secondary Outcome Measures  ICMJE
 (submitted: June 5, 2019)
  • Proportion of failure [ Time Frame: 3 days ]
    Failure is defined as:
    • HFNC failure (composite failure criterion validated by an independent committee)
    • worsening of mWCAS score ≥ 1 point
    • hypercapnic acidosis (pH ≤7.30 and pCO2≥8kPa)
    • significant apnea (apnea with desaturation <90% and / or bradycardia <90/min)
    Anytime over the first 3 days after inclusion
  • Causes of failure [ Time Frame: 3 days ]
    Failure is defined as:
    • HFNC failure (composite failure criterion validated by an independent committee)
    • worsening of mWCAS score ≥ 1 point
    • hypercapnic acidosis (pH ≤7.30 and pCO2≥8kPa)
    • significant apnea (apnea with desaturation <90% and / or bradycardia <90/min)
    Anytime over the first 3 days after inclusion
  • Duration of ventilation [ Time Frame: maximum 3 months ]
    Duration of ventilation (high flow nasal cannula, invasive, non-invasive) in hours. This data will be collected at critical care unit discharge.
  • Length of stay [ Time Frame: maximum 3 months ]
    Length of stay in days. This data will be collected at hospital discharge.
  • Oxygenation evaluation [ Time Frame: 2 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H2.
  • Oxygenation evaluation [ Time Frame: 12 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H12.
  • Oxygenation evaluation [ Time Frame: 24 hours ]
    Evolution of FiO2 and SpO2/FiO2 ratio between inclusion and H24.
  • Tolerance evaluation [ Time Frame: maximum 3 months ]
    Proportion of skin lesions, vomiting/regurgitation and exclusive enteral nutrition. This data will be collected at critical care unit discharge.
  • Comfort evaluation [ Time Frame: 2 hours ]
    EDIN score (Scale of pain and discomfort of the newborn) between inclusion and H2
  • Feasibility evaluation [ Time Frame: 48 hours ]
    Proportion of children in the prone position repositioned definitively in the supine position before performing the cumulative 24 hours of PP, cumulative hours of prone position in the first 48 hours
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Prone Position in Acute Bronchiolitis
Official Title  ICMJE Effect of Prone Position on the Use of Non-invasive and Invasive Ventilation in Infants With Moderate to Severe Acute Bronchiolitis
Brief Summary

Acute viral bronchiolitis is the leading cause of community-acquired acute respiratory failure in developed countries (20 000 to 30 000 hospitalizations each year in France). Between 5% and 22% of these children are hospitalized in a critical care unit to benefit from a respiratory support.

Non-invasive ventilation, in particular the nasal Continuous Positive Airway Pressure (nCPAP), reduces the work of breathing in children with bronchiolitis and is associated with decreased morbidity and hospitalization costs compared with invasive ventilation. Nowadays, this technique is considered as the gold standard in the pediatric intensive care units (PICU) in France. High Flow Nasal Cannula (HFNC) has been proposed as an alternative to the nCPAP because of its better tolerance and simplicity of implementation. However, the proportion of failure remains high (35 to 50%), providing only a partial response to the care of these children, especially prior to the PICU.

In a physiological study (NCT02602678, article published), it has been demonstrated that prone position (PP) decrease, by almost 50%, the respiratory work of breathing and improve the respiratory mechanics in infants hospitalized in intensive care units for bronchiolitis.

Investigators hypothesize that prone position, during High Flow Nasal Cannula (HFNC), would significantly reduce the use of non-invasive ventilation (nCPAP and others) or invasive ventilation, as compared to supine position during HFNC, in infants with moderate to severe viral bronchiolitis.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Acute Viral Bronchiolitis
Intervention  ICMJE
  • Procedure: Supine position (SP)

    Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.

    Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.

  • Procedure: Prone position (PP)

    Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.

    Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.

Study Arms  ICMJE
  • Supine position (SP)
    Supine position (SP) combined with HFNC
    Intervention: Procedure: Supine position (SP)
  • Experimental: Prone position (PP)
    Prone position (SP) combined with HFNC
    Intervention: Procedure: Prone position (PP)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 5, 2019)
420
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2022
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Infant under 6 months
  • Hospitalized in critical care unit (continuous monitoring unit or intensive care unit)
  • With a clinical diagnosis of acute viral bronchiolitis during the epidemic period (criterion of the American Academy of Pediatrics 2014)
  • m-WCAS score ≥ 3 and / or hypercapnic acidosis with pH <7.35 and pCO2> 50mmHg (6.7 kPa)
  • Informed consent signed by at least one of the parents with oral consent of the other parent (and / or legal guardian) recorded in the medical file.

Exclusion Criteria:

  • Infant admitted with criteria for invasive or non-invasive ventilation (hypercapnic acidosis with pH <7.25 without ventilatory support, hypoxia with impossibility of maintaining SpO2> 92% whatever the FiO2, more than 3 significant apneas per hour, severe consciousness disorder)
  • Patient already positioned in the prone position before randomization
  • Significant comorbidities with a history of respiratory pathology (bronchodysplasia), Ear Nose and Throat pathology (pharyngolaryngomalacia) or neuromuscular and / or hemodynamically significant congenital heart disease.
  • Contraindication to Prone position : recent abdominal surgery (laparoschisis or omphalocele) or recent sternotomy
  • Patient who is not affiliated (or does not benefit from) to a national social security system
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 6 Months   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Florent BAUDIN, Dr 04 72 12 97 35 ext +33 florent.baudin@chu-lyon.fr
Contact: Tiphanie GINHOUX 04 27 85 77 23 ext +33 tiphanie.ginhoux@chu-lyon.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03976895
Other Study ID Numbers  ICMJE 69HCL19_0333
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Hospices Civils de Lyon
Study Sponsor  ICMJE Hospices Civils de Lyon
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Hospices Civils de Lyon
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院